Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	ADMA Biologics	LogicBio Therapeutics	Protalix BioTherapeutics	Gamida Cell	Genfit
Symbol	NASDAQ:ADMA	NASDAQ:LOGC	NYSEAMERICAN:PLX	NASDAQ:GMDA	NASDAQ:GNFT
Price Information
Current Price	$1.62	$4.43	$2.87	$6.30	$4.11
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.6	1.3	1.3	1.4	1.3
Analysis Score	3.5	3.5	3.5	3.5	3.3
Community Score	3.0	2.4	2.4	2.7	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.0	0.0	0.0	0.0
Earnings & Valuation Score	0.6	0.6	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$7.80	$18.50	$7.00	$20.25	$51.00
% Upside from Price Target	381.48% upside	317.61% upside	143.90% upside	221.43% upside	1,140.88% upside
Trade Information
Market Cap	$196.47 million	$142.47 million	$130.25 million	$152.59 million	$188.14 million
Beta	1.84	1.34	2.87	2.03	1.33
Average Volume	6,460,805	131,900	1,226,719	782,690	184,713
Sales & Book Value
Annual Revenue	$29.35 million	N/A	$54.69 million	N/A	$45.88 million
Price / Sales	6.69	N/A	2.38	N/A	4.10
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.44 per share	$1.84 per share	($4.74) per share	$1.44 per share	$2.49 per share
Price / Book	3.68	N/A	-0.61	N/A	1.65
Profitability
Net Income	$-48,280,000.00	$-40,130,000.00	$-18,280,000.00	$-34,350,000.00	$-72,960,000.00
EPS	($0.92)	($1.78)	($1.23)	($1.69)	($1.97)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	287.00	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-166.01%	N/A	-10.84%	N/A	N/A
Return on Equity (ROE)	-98.83%	-117.64%	N/A	-112.47%	N/A
Return on Assets (ROA)	-37.21%	-76.85%	-9.74%	-65.09%	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	1.40%	0.40%	N/A	N/A	5.74%
Current Ratio	8.47%	6.21%	1.37%	5.39%	5.71%
Quick Ratio	4.24%	6.21%	1.07%	5.39%	5.71%
Ownership Information
Institutional Ownership Percentage	48.90%	33.78%	14.28%	N/A	0.41%
Insider Ownership Percentage	11.70%	23.40%	1.64%	N/A	N/A
Miscellaneous
Employees	406	39	207	110	203
Shares Outstanding	121.28 million	32.16 million	45.38 million	24.22 million	45.78 million
Next Earnings Date	8/4/2021 (Estimated)	8/9/2021 (Estimated)	5/14/2021 (Confirmed)	8/10/2021 (Estimated)	7/1/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	Nash Market to Witness Huge Growth by 2028 \| Novo Nordisk, Galmed Pharmaceuticals, Genfit Intercept, Galectin Therapeutics and Gilead Sciences. – Clark County Blog - Clark County Blog clarkcountyblog.com - May 13 at 10:53 AM
	Ninety One UK Ltd - Form 8.3 - Gamesys Group Plc - Yahoo Finance UK uk.finance.yahoo.com - May 12 at 11:37 PM
	The Diverse Income Trust Plc - Redemption of Ordinary Shares - Yahoo Finance UK uk.finance.yahoo.com - May 12 at 6:37 PM
	Genfit's Post-NASH Plans Center On ACLF, Cholestatic Liver Disease - Scrip scrip.pharmaintelligence.informa.com - May 12 at 6:37 PM
	Genfit SA Stock Shows Every Sign Of Being Possible Value Trap - Yahoo Finance finance.yahoo.com - May 12 at 6:37 PM
	GENFIT: Reports First Quarter 2021 Financial Information - GlobeNewswire globenewswire.com - May 12 at 6:37 PM
	Genfit SA Stock Shows Every Sign Of Being Possible Value Trap - GuruFocus.com gurufocus.com - May 12 at 1:37 PM
	Non-Alcoholics Steatohepatitis Market 2021 Industry Analysis, Trends, and Forecast : Genfit, Gilead Sciences, 1Galectin Therapeutics, Galmed Pharmaceuticals – Clark County Blog - Clark County Blog clarkcountyblog.com - May 11 at 8:08 PM
	GENFIT Provides Pipeline Update and Launch of New Clinical - GlobeNewswire globenewswire.com - May 11 at 8:08 PM
	Obeticholic Acid Market 2021 Overview, Industry by Type, by Manufacturers : Genfit SA, Intercept Pharmaceuticals, Inc., Galmed Pharmaceuticals Ltd., Tobira Therapeutics, Inc. – Test & Measurement - Test & Measurement testmeasurement.com.au - May 11 at 10:04 AM
	GENFIT Annual Combined General Meeting of June 15, 2021 - - GlobeNewswire globenewswire.com - May 10 at 7:26 PM
	Nonalcoholic Steatohepatitis (NASH) Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast To 2025 – BeverageManager .Net - BeverageManager .Net beveragemanager.net - May 10 at 9:23 AM
	Nuclear Receptor ROR Gamma Market Overview, Growth Rate and Future Scenario 2027\| Genfit SA, GlaxoSmithKline Plc, Aurigene Discovery Technologies – BeverageManager .Net - BeverageManager .Net beveragemanager.net - May 9 at 7:59 AM
	Nash Market Research Report, Growth Trends and Competitive Analysis 2021-2027 \| Novo Nordisk, Galmed Pharmaceuticals, Genfit Intercept, Galectin Therapeutics and Gilead Sciences. – BeverageManager .Net - BeverageManager .Net beveragemanager.net - May 8 at 7:55 PM
	Increasing Demand of Nonalcoholic Steatohepatitis (Nash) Market by 2027 \| GENFIT SA, Viking Therapeutics, Tobira Therapeutics, Inc. – Clark County Blog - Clark County Blog clarkcountyblog.com - May 7 at 8:22 AM
	Global Non-Alcoholic Steatohepatitis Management Market 2021:Sets the Table for Continued Growth\|\|Key Players-Galmed Pharmaceuticals Ltd, Gemphire Therapeutics, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc - The Manomet Current manometcurrent.com - May 6 at 8:40 AM
	Global Roundup: GENFIT Launches NASH Diagnostic Kit in US, Canada \| BioSpace - BioSpace biospace.com - May 5 at 5:38 PM
	Insights on the Non-Alcoholic Steatohepatitis (NASH) Biomarker Global Market to 2028 - by Type, Industry Verticals and Region - Yahoo Finance finance.yahoo.com - May 5 at 7:38 AM
	Peroxisome Proliferator Activated Receptor Delta Market to Witness Robust Expansion by 2026 \| Chipscreen Biosciences Ltd, Connexios Life Sciences Pvt Ltd, CymaBay Therapeutics Inc, Genfit SA, Inventiva, Mitobridge Inc - Clark County Blog clarkcountyblog.com - May 3 at 11:24 PM
	Francisco Partners, TPG buy Dell's cloud business Boomi for $4 billion - Yahoo Finance UK uk.finance.yahoo.com - May 3 at 8:23 AM
	GENFIT announces the launch by Labcorp of NASHnext® A Novel - GlobeNewswire globenewswire.com - May 3 at 8:23 AM
	Short Interest in Genfit SA (NASDAQ:GNFT) Grows By 48.9% americanbankingnews.com - May 1 at 10:00 AM
	Nuclear Receptor ROR Gamma Market Size, Status, Global Demands and Top Manufacturers 2021 \| Genfit SA, GlaxoSmithKline Plc, Aurigene Discovery Technologies, Beijing Hanmi Pharmaceutical, Biogen Inc, AbbVie Inc - Clark County Blog clarkcountyblog.com - April 30 at 7:44 PM
	Cardiometabolic Drug Market Size 2021 Global Business Trends, Modest Analysis, Statistics, Forecast 2021-2025 \| Prudent Markets - Clark County Blog clarkcountyblog.com - April 29 at 7:41 PM
	Nash Drugs Market (Covid-19 Analysis) SWOT Analysis, Key Indicators, Forecast 2028 \| Galmed Pharmaceuticals, Genfit SA, Intercept Pharmaceuticals, Inc., Conatus Pharmaceuticals - Jumbo News jumbonews.co.uk - April 29 at 7:41 PM

Date	Company	Brokerage	Action
4/5/2021	ADMA Biologics	Jefferies Financial Group	Reiterated Rating
4/1/2021	ADMA Biologics	Raymond James	Lower Price Target
3/26/2021	ADMA Biologics	Maxim Group	Reiterated Rating
1/4/2021	ADMA Biologics	HC Wainwright	Lower Price Target
8/6/2020	ADMA Biologics	Oppenheimer	Initiated Coverage
8/12/2019	ADMA Biologics	Dawson James	Downgrade
4/4/2019	ADMA Biologics	WBB Securities	Upgrade
3/10/2021	LogicBio Therapeutics	JMP Securities	Initiated Coverage
3/1/2021	LogicBio Therapeutics	William Blair	Reiterated Rating
5/22/2020	LogicBio Therapeutics	Chardan Capital	Reiterated Rating
5/1/2019	LogicBio Therapeutics	Roth Capital	Initiated Coverage
11/13/2018	LogicBio Therapeutics	Barclays	Initiated Coverage
3/15/2021	Gamida Cell	Needham & Company LLC	Lower Price Target
3/9/2021	Gamida Cell	Piper Sandler	Lower Price Target
6/30/2020	Gamida Cell	Evercore ISI	Initiated Coverage
2/26/2020	Gamida Cell	BMO Capital Markets	Lower Price Target
11/21/2018	Gamida Cell	CIBC	Initiated Coverage
4/5/2021	Genfit	SVB Leerink	Lower Price Target
2/12/2021	Genfit	Bryan, Garnier & Co	Upgrade
7/23/2020	Genfit	Stifel Nicolaus	Upgrade
6/25/2020	Genfit	Bank of America	Initiated Coverage
5/22/2020	Genfit	B. Riley	Boost Price Target
5/13/2020	Genfit	Kepler Capital Markets	Downgrade
5/12/2020	Genfit	Oddo Bhf	Downgrade

(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources